Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

March 26, 2018

Primary Completion Date

June 15, 2019

Study Completion Date

March 31, 2025

Conditions
Aggressive Non-Hodgkin Lymphoma
Interventions
DRUG

Pixantrone

6 cycles - dose = 80mg/m²

OTHER

Ifosfamide

6 cycles - 1500 mg/m2

OTHER

Etoposide

6 cycles - 150 mg/m2

OTHER

Rituximab

6 cycles - 375 mg/m2

PROCEDURE

Transplant

after 2 or 6 cycles

Trial Locations (22)

Unknown

AZ Sint Jan, Bruges

Institut Jules Bordet - Centre des tumeurs de l'ULB, Brussels

Centre Hospitalier de Jolimont, Haine-Saint-Paul

CH d'Avignon, Avignon

Centre Hospitalier de la Côte Basque, Bayonne

CHU Jean Minjoz, Besançon

Hôpital Haut-Lévèque, Bordeaux

Centre Hospitalier William Morey, Chalon-sur-Saône

Clinique Victor Hugo, Le Mans

CHRU de Lille, Lille

CHU Lyon Sud, Lyon

CHU de la Conception, Marseille

Centre Lacassagne, Nice

Hopital La Pitié Salpétriere, Paris

Hôpital St louis, Paris

CHU de Poitiers, Poitiers

Centre Hospitalier Annecy Genevois, Pringy

CH de Cornouaille, Quimper

Hôpital Robert Debré, Reims

CHU de Rouen, Rouen

CHU de Strasbourg, Strasbourg

CHU de Tours, Tours

All Listed Sponsors
lead

The Lymphoma Academic Research Organisation

OTHER